Takeda selected for the eighth consecutive year for Dow Jones Sustainability Asia Pacific Index

Takeda selected for the eighth consecutive year for Dow Jones Sustainability Asia Pacific Index

September 15, 2017

Osaka, Japan, September 15, 2017 – Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced that for the eighth consecutive year it has been selected for the Dow Jones Sustainability Asia Pacific Index ("DJSI Asia Pacific"), which is one of the world foremost indices for Socially Responsible Investment (SRI)*. In this year, Takeda received particularly high marks in the Environment category.

DJSI Asia Pacific is part of the Dow Jones Sustainability Indexes (DJSI), which is provided by S&P Dow Jones Indices LLC of the United States. It is designed for companies in the developed Asia Pacific markets and comprises 152 companies this year, including 72 Japanese companies that are leading the way in terms of sustainability among the 614 companies in the region. Dow Jones assesses and selects leading sustainability-driven companies based on economic, environmental, and social criteria. Thus it serves as an important indicator for investors considering corporate social responsibility (CSR) performance.

In addition to DJSI, Takeda is included in multiple SRI index/universe such as FTSE4Good Global Index (FTSE Russel), Ethibel EXCELLENCE Investment Register (Forum Ethibel) and Oekom Prime Status (Oekom).  Takeda also clinched recognition by Corporate Knights as one of the 2017 Global 100 Most Sustainable Corporations in the World Index, for the second consecutive year.

Name of
Index/ Investment Universe/Ratings



Number of

Dow Jones Sustainability Asia Pacific Index

S&P Dow Jones Indices


8th consecutive year

FTSE4Good Global Index

FTSE Russel


13th consecutive year

Ethibel EXCELLENCE Investment Register

Forum Ethibel


three times

Prime Status



first time

Global 100 Most Sustainable Corporations in the World Index

Corporate Knights


2nd consecutive year

For Takeda, CSR is rooted in putting the patient in the center and operating a pharmaceutical business that creates outstanding products. The company also strives to maintain and improve sound business processes, and to engage in activities to promote a sustainable society as a good corporate citizen. This will help Takeda to build trust with society, reinforce its reputation, and further develop the pharmaceutical business.

SRI evaluates investments in companies not only in terms of financial performance, but also with an emphasis on corporate social responsibility performance from social, ethical, environmental, and other perspectives.

About Takeda
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. Around 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit https://www.takeda.com/newsroom/.


Media Contact:
Satoko Imai
[email protected]